Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Coxsackievirus A21 |
Synonyms | |
Therapy Description |
CAVATAK (Coxsackievirus A21) is a naturally occuring enterovirus which infect and lysis tumor cells (PMID: 17391493, PMID: 32529026). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Coxsackievirus A21 | CAVATAK|CVA21|V937|Gebasaxturev | CAVATAK (Coxsackievirus A21) is a naturally occuring enterovirus which infect and lysis tumor cells (PMID: 17391493, PMID: 32529026). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02307149 | Phase I | Coxsackievirus A21 Ipilimumab | Study of Intratumoral CAVATAK (Coxsackievirus A21) and Ipilimumab in Patients With Advanced Melanoma | Completed | USA | 0 |
NCT02043665 | Phase I | Coxsackievirus A21 | Systemic Treatment Of Resistant Metastatic Disease Employing CVA21 and Pembrolizumab in Non-small Cell Lung Cancer and Bladder Cancer (STORM/ KEYNOTE-200) (STORM) | Completed | USA | GBR | AUS | 0 |